Weiss Ratings Reaffirms Sell (E+) Rating for 111 (NASDAQ:YI)

Key Points

• 111 Inc. (NASDAQ:YI) has received a "sell (e+)" rating from Weiss Ratings, reaffirming negative investor sentiment.
• As of Tuesday, the stock price opened at $6.99, with a market capitalization of $60.39 million and a 1-year PE ratio of -10.92.
• Recent institutional investments have significantly altered stock ownership, with JPMorgan Chase boosting its stake by 43,619.9% in the fourth quarter.

111 (NASDAQ:YI - Get Free Report)'s stock had its "sell (e+)" rating reissued by equities research analysts at Weiss Ratings in a research note issued to investors on Tuesday,Weiss Ratings reports.

111 Price Performance

Shares of NASDAQ YI traded down $0.06 during mid-day trading on Tuesday, hitting $6.93. The company had a trading volume of 23,124 shares, compared to its average volume of 7,725. 111 has a 12 month low of $4.14 and a 12 month high of $12.00. The stock has a market cap of $59.88 million, a price-to-earnings ratio of -10.83 and a beta of 0.44. The firm's 50 day simple moving average is $7.70 and its two-hundred day simple moving average is $7.62.

111 (NASDAQ:YI - Get Free Report) last released its quarterly earnings data on Thursday, June 19th. The company reported ($0.20) earnings per share for the quarter. The firm had revenue of $486.35 million during the quarter.

Hedge Funds Weigh In On 111

A number of institutional investors and hedge funds have recently modified their holdings of the company. FIL Ltd bought a new position in 111 in the 4th quarter valued at about $450,000. JPMorgan Chase & Co. grew its position in 111 by 43,619.9% during the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock worth $191,000 after acquiring an additional 305,339 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in 111 in the first quarter worth about $92,000. Finally, Deuterium Capital Management LLC bought a new stake in 111 in the first quarter valued at approximately $81,000. Institutional investors and hedge funds own 21.32% of the company's stock.

111 Company Profile

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.